1. Efficacy and Safety of Iclepertin (BI 425809) in Patients With Schizophrenia: CONNEX, A Phase III Randomized Controlled Trial Program. (April 2023) Authors: Wunderlich, Glen; Blahova, Zuzana; Hake, Sanjay; Ikezawa, Satoru; Marder, Stephen; Falkai, Peter; Krystal, John H. Journal: CNS spectrums Issue: Volume 28:Number 2(2023) Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. (March 2021) Authors: Fleischhacker, W Wolfgang; Podhorna, Jana; Gröschl, Martina; Hake, Sanjay; Zhao, Yihua; Huang, Songqiao; Keefe, Richard S E; Desch, Michael; Brenner, Ronald; Walling, David P; Mantero-Atienza, Emilio; Nakagome, Kazuyuki; Pollentier, Stephane Journal: Lancet Issue: Volume 8:Number 3(2021) Page Start: 191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S40. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERISED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: INITIAL EXPERIENCE OF A LARGE-SCALE MULTICENTRE RANDOMISED CLINICAL TRIAL. (18th May 2020) Authors: Hake, Sanjay; Huang, Songqiao; McDonald, Sean; Pollentier, Stephane; Podhorna, Jana Journal: Schizophrenia bulletin Issue: Volume 46(2020)Supplement 1 Page Start: S47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗